Novo Nordisk raises its full-year outlook following strong sales of the Wegovy pill
Wegovy pills sold for 5.4 billion kroner in the third quarter. Novo Nordisk raised its 2026 adjusted sales and operating profit outlook to between a 2% increase and a 2% decline.
- Wegovy pills sold for 5.4 billion kroner in the third quarter.
- Novo Nordisk raised its 2026 adjusted sales and operating profit outlook to between a 2% increase and a 2% decline.
Outlets: Berlingske, Free Malaysia Today, International: Top News And Analysis, La Tercera, TimesLIVE
Written by AI from the outlets' reporting and checked automatically; it can contain mistakes. How Daily Brief works · Privacy